Business Model Breakdown
How Resmed Inc Makes Money
RMD
Market Cap
$28.4B
Annual Revenue
$4.7B
Profit Margin
27.4%
The Short Version
ResMed Inc. designs, manufactures, and distributes medical devices and digital health solutions primarily focused on treating and managing sleep-disordered breathing (such as sleep apnea) and chronic respiratory conditions like COPD. The company generates revenue by selling its range of devices, including CPAP machines, masks, and ventilators, along with providing cloud-connected software platforms that enable patient monitoring and data management for healthcare providers, thus facilitating a connected care ecosystem.
Where the Revenue Comes From
Sales of devices (CPAP, APAP, ventilators, masks, accessories)
Digital health and software solutions (subscription-based cloud services)
Who buys: Patients suffering from sleep apnea and chronic respiratory diseases, hospitals, sleep clinics, physicians, and home healthcare providers globally.
Why It Works (Competitive Advantages)
- ✔Strong brand recognition and reputation in sleep and respiratory care.
- ✔Extensive R&D and intellectual property in connected medical devices and digital health platforms.
- ✔Established global distribution networks and clinical relationships.
Economic Moat: Narrow (Brand Power, Intangible Assets/IP, Switching Costs)
What Our Analysis Says
DVR Score as of June 8, 2026
ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically targets '10x growth potential within the next 3-5 years.' Given RMD's current large-cap status ($28.44B), achieving a market capitalization exceeding $284 billion in such a timeframe is extraordinarily improbable. The company's growth trajectory is stable and incremental, not exponential. No material changes or revolutionary catalysts have emerged since the last analysis that would realistically alter RMD's fundamental growth profile to support hyper-growth. While a sound investment for stable growth, it does not align with our hyper-growth criteria for a 10x return.